The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment patterns in pancreatic cancer: Differences between expert and community practitioners.
 
Ryan P. Topping
No Relationships to Disclose
 
E. Gabriela Chiorean
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Celgene; Eisai; Five Prime Therapeutics; Halozyme; Ipsen; Legend Biotech; Seagen; Vicus Therapeutics
Research Funding - AADi (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); FibroGen; Halozyme (Inst); Ignyta (Inst); Incyte (Inst); Lilly (Inst); MacroGenics (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Legend Biotech; Seagen
 
Dan Laheru
No Relationships to Disclose
 
Michael J. Pishvaian
Stock and Other Ownership Interests - Perthera
Honoraria - Caris Life Sciences; Celgene; Halozyme; Sirtex Medical
Consulting or Advisory Role - ARMO BioSciences; AstraZeneca/MedImmune; Caris Life Sciences; Celgene; Ignyta; Merck; Perthera; Rafael Pharmaceuticals; RenovoRx; Sirtex Medical
Research Funding - ARMO BioSciences (Inst); Bavarian Nordic (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Curegenix (Inst); FibroGen (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Regeneron (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Perthera patient matching algorithm
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Caris Life Sciences; Merck; Perthera; Sirtex Medical
 
Andrea Wang-Gillam
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Jacobio; Repugene; Tyme
Research Funding - AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CTI (Inst); Gossamer Bio (Inst); Hutchison MediPharma (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); pfizer (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Verastem (Inst); Xcovery (Inst)
 
Timothy A. Quill
No Relationships to Disclose
 
Andrew H. Ko
Honoraria - Clinical Care Options; Dava Oncology; Elsevier; OncLive; PER; Pharmatecture; PlatformQ Health; Research to Practice; Xcenda
Consulting or Advisory Role - ERYTECH Pharma; Gilead Sciences; Gritstone Bio; Imugene; MORE Health; SynCoreBio
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Halozyme (Inst); Merck (Inst); Merrimack (Inst)